Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05377996 | A Study of XMT-1660 in Participants With Solid Tumors | PHASE1 | RECRUITING | 319 | — | — | Aug 15, 2022 | May 1, 2027 | Apr 14, 2026 | 26 | United States |
Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of XMT-1660
Assess the safety and tolerability of XMT-1660 by determining the number of patients with adverse events from date of first dose to 30 days post last dose
The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Arm | Type | Description |
|---|---|---|
| XMT-1660 | EXPERIMENTAL | Single arm XMT-1660 alone (monotherapy) |
| Name | Type | Description |
|---|---|---|
| XMT-1660 | DRUG | XMT-1660 will be administered through a vein in your arm or port catheter (intravenously) |
Inclusion Criteria: * Recurrent or advanced solid tumor and has disease * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Participants in DES must have at least one non-target lesion as defined by RECIST version 1.1. Participants in Backfill Cohorts and EXP must have at least ...